Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Diabetes accounts for roughly 30% of all neuropathy cases, with chronic hyperglycemia damaging small blood vessels that supply peripheral nerves
The FDA approved liraglutide as Saxenda in 2014 and semaglutide as Wegovy in 2021
Author Contributions Conceived and designed the experiments: JM JV FVP
[1] Contact your GP or diabetes care team if you notice: Consistently elevated blood glucose readings HbA1c rising above your agreed target Unexplained weight gain Return of diabetes symptoms (increased thirst, frequent urination, fatigue) Severe and persistent abdominal pain (with or without vomiting), which could indicate pancreatitis Symptoms of gallbladder disease (pain in upper right abdomen, nausea, vomiting) Signs of dehydration (dizziness, dry mouth, reduced urination) New or worsening visual symptoms, particularly if you have diabetic retinopathy Your healthcare provider may consider dose escalation (Ozempic starts at 0.25 mg weekly for 4 weeks as an initiation dose only, then 0.5 mg, with possible increases to 1 mg and 2 mg weekly doses if needed and tolerated) or investigate other factors affecting your diabetes control
US$ 27.45
US$ 27.64
US$ 25.53
US$ 25.05
US$ 24.73
